EricJonaschMD

PubMed

• YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial.
  Chad Tang, Kieko Hara, Alexander D Sherry, Alejandra G Serrano, Larisa V Kostousov, Sharia D Hernandez, Wei Lu, Li Shen, Amishi Y Shah, Eric Jonasch, Jose A Karam, Sur...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
• Belzutifan for von Hippel-Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study.
  Lliopoulos, O., Beckermann, K., Oudard, S., Iversen, A., Goldberg, C., Fu, W., Perini, R., Liu, Y., Linehan, W., Else, T., Jonasch, E., Narayan, V., Maughan, B., Maran...> ;Clinical Cancer Research. 2024 Feb 23
• Epidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United St...
  Berman, R., Eric Jonasch, Yan Song, Jonathan Freimark, Richard Berman, Ha Nguyen, James Signorovitch, Murali Sundaram> ;Orphanet Journal of Rare Diseases. 2024 Feb 16
• NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.
  Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I Carlo, Toni K Choueiri, Brian A Costello, Ithaar ...> ;Journal of the National Comprehensive Cancer Network. 2024 Feb 1
• 1 citations
  Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
  Andrew W Hahn, Devaki Shilpa Surasi, Paul V Viscuse, Tharakeswara K Bathala, Andrew J Wiele, Matthew T Campbell, Amado J Zurita, Amishi Y Shah, Eric Jonasch, Jianjun G...> ;The Oncologist. 2023 Nov 30
• 2 citations
  Phase I LITESPARK-001 study of belzutifan for advanced solid tumors: Extended 41-month follow-up in the clear cell renal cell carcinoma cohort.
  Eric Jonasch, Todd M Bauer, Kyriakos P Papadopoulos, Elizabeth R Plimack, Jaime R Merchan, David F McDermott, M Dror Michaelson, Leonard J Appleman, Ananya Roy, Rodolf...> ;European Journal of Cancer. 2024 Jan 1
• 1 citations
  SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
  Xian-De Liu, Yan-Ting Zhang, Daniel J McGrail, Xuesong Zhang, Truong Lam, Anh Hoang, Elshad Hasanov, Ganiraju Manyam, Christine B Peterson, Haifeng Zhu, Shwetha V Kuma...> ;Clinical Cancer Research. 2023 Oct 2
• 3 citations
  Interferon signaling promotes tolerance to chromosomal instability during metastatic evolution in renal cancer.
  Luigi Perelli, Federica Carbone, Li Zhang, Justin K Huang, Courtney Le, Hania Khan, Francesca Citron, Edoardo Del Poggetto, Tony Gutschner, Hideo Tomihara, Melinda Soe...> ;Nature Cancer. 2023 Jul 1
• 2 citations
  Management of Brain Metastases in Metastatic Renal Cell Carcinoma.
  Elshad Hasanov, Eric Jonasch> ;Hematology/oncology Clinics of North America. 2023 Oct 1
• 3 citations
  Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy.
  Daniel D Shapiro, Niki Millward Zacharias, Durga N Tripathi, Menuka Karki, Jean-Philippe Bertocchio, Melinda Soeung, Rong He, Mary E Westerman, Jianjun Gao, Priya Rao,...> ;Clinical and Translational Medicine. 2023 May 1
• 6 citations
  The glycoprotein CD147 defines miRNA-enriched extracellular vesicles that derive from cancer cells.
  Song Yi Ko, WonJae Lee, Melanie Weigert, Eric Jonasch, Ernst Lengyel, Honami Naora> ;Journal of Extracellular Vesicles. 2023 Apr 1
• 2 citations
  Cytoreductive Nephrectomy for Patients with Metastatic Sarcomatoid and/or Rhabdoid Renal Cell Carcinoma Treated with Immune Checkpoint Therapy.
  Andrew W Hahn, Ritesh R Kotecha, Paul V Viscuse, Alberto C Pieretti, Andrew J Wiele, Eric Jonasch, Chung-Han Lee, Jianjun Gao, Amado J Zurita, Amishi Y Shah, Matthew T...> ;European Urology Focus. 2023 Sep 1
• 1 citations
  Plasma and Urine Free Glycosaminoglycans as Monitoring and Predictive Biomarkers in Metastatic Renal Cell Carcinoma: A Prospective Cohort Study.
  Francesco Gatto, Sinisa Bratulic, Eric Jonasch, Angelo Limeta, Francesca Maccari, Fabio Galeotti, Nicola Volpi, Sven Lundstam, Jens Nielsen, Ulrika Stierner> ;JCO Precision Oncology. 2023 Feb 1
• 2 citations
  Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.
  Eric Jonasch, Yan Song, Jonathan Freimark, Richard Berman, Ha Nguyen, James Signorovitch, Murali Sundaram> ;Clinical Genitourinary Cancer. 2023 Apr 1
• 18 citations
  Noninvasive detection of any-stage cancer using free glycosaminoglycans.
  Sinisa Bratulic, Angelo Limeta, Saeed Dabestani, Helgi Birgisson, Gunilla Enblad, Karin Stålberg, Göran Hesselager, Michael Häggman, Martin Höglund, Oscar E Simonson, ...> ;Proceedings of the National Academy of Sciences of the United States of America. 2022 Dec 13
• 13 citations
  Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergy.
  Patrycja Nowak-Sliwinska, Judy R van Beijnum, Christian J Griffioen, Zowi R Huinen, Nadine Grima Sopesens, Ralph Schulz, Samir V Jenkins, Ruud P M Dings, Floris H Groe...> ;Angiogenesis. 2023 May 1
• 2 citations
  Systemic Therapy Development in Von Hippel-Lindau Disease: An Outsized Contribution from an Orphan Disease.
  Vivek Narayan, Eric Jonasch> ;Cancers. 2022 Oct 28
• 3 citations
  Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay.
  D J McGrail, P G Pilié, N U Rashid, L Voorwerk, M Slagter, M Kok, E Jonasch, M Khasraw, A B Heimberger, N T Ueno, R Ferrarotto, J T Chang, S-Y Lin> ;Annals of Oncology. 2022 Nov 1
• 12 citations
  An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma.
  Elshad Hasanov, Debra Nana Yeboa, Mathew D Tucker, Todd A Swanson, Thomas Hendrix Beckham, Brian Rini, Chibawanye I Ene, Merve Hasanov, Sophie Derks, Marion Smits, Sha...> ;CA. 2022 Sep 1
• 22 citations
  A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy.
  Pavlos Msaouel, Sangeeta Goswami, Peter F Thall, Xuemei Wang, Ying Yuan, Eric Jonasch, Jianjun Gao, Matthew T Campbell, Amishi Yogesh Shah, Paul Gettys Corn, Alda L Ta...> ;Science Translational Medicine. 2022 Apr 20
• 4 citations
  Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.
  Elshad Hasanov, Isabel Pimentel, Mara Cruellas, Mark A Lewis, Eric Jonasch, Judith Balmaña> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2022 Apr 1
• 52 citations
  From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.
  Choueiri, T., Albiges, L., Atkins, M., Bakouny, Z., Bratslavsky, G., Braun, D., Haas, N., Haanen, J., Hakimi, A., Jewett, M., Jonasch, E., Kaelin, W., Kapur, P., Labak...> ;Clinical Cancer Research. 2022 Mar 1
• 3 citations
  Patient-reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas: Results from a Global Patient Survey in 43 Countries.
  Rachel Giles, Deborah Maskens, Robert Bick, Robin Martinez, Malcolm Packer, Daniel Heng, James Larkin, Axel Bex, Michael Jewett, Eric Jonasch, Sara MacLennan> ;European Urology Open Science. 2022 Mar 1
• 11 citations
  Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
  Eric Jonasch, Michael B Atkins, Simon Chowdhury, Paul Mainwaring> ;Cancers. 2022 Jan 27
• 2 citations
  Sunitinib-Related Osteonecrosis of the External Auditory Canal: Case Report.
  Arturo Eguia, Eric Jonasch, Paul Gidley> ;Otolaryngology--Head and Neck Surgery. 2022 Sep 1
• Join now to see all

Journal Articles

• VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell Carcinoma  
  Eric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine

Lectures

• Comparison of clinical outcomes with first-line pazopanib in clinical trial eligible and non-clinical trial eligible patients with renal cell carcinoma. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
• Enrichment and Optimization of Anti-VEGF Targeted Strategies in Metastatic Renal Cell Carcinoma 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Other

• Molecular biology and pathogenesis of von Hippel-Lindau disease 
  Jonasch E, Plon SE
  http://www.uptodate.com/contents/molecular-biology-and-pathogenesis-of-von-hippel-lindau-disease
  UpToDate, Wolters Kluwer Health - 2012-06-19
• Immunotherapy of renal cell carcinoma 
  Jonasch E, George D
  http://www.uptodate.com/contents/immunotherapy-of-renal-cell-carcinoma
  UpToDate, Wolters Kluwer Health - 2012-09-17
• Clinical features, diagnosis, and management of von Hippel-Lindau disease 
  Jonasch E, Plon SE
  http://www.uptodate.com/contents/clinical-features-diagnosis-and-management-of-von-hippel-lindau-dis
  UpToDate, Wolters Kluwer Health - 2013-02-05